Solvay seeks European approval for fixed-dose combination fenofibrate/metformin product

By Lisa Kerner

Charlotte, N.C., July 19 - Solvay submitted an application to the European Medicines Evaluation Agency seeking approval for Synordia, a fixed-dose combination of a lipid-lowering drug and an oral antidiabetic (fenofibrate and metformin) to lower both blood lipids and blood glucose.

The pill is intended to increase patient convenience and improve compliance for patients stabilized on the two medications.

In a phase 3 clinical study of more than 1,000 patients, Synordia was shown to be efficacious and is well accepted.

Previous trials also demonstrated the benefits of the combination therapy in patients with type 2 diabetes.

Solvay is an international chemical and pharmaceutical group based in Brussels, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.